Olympus Corporation
Stock Price Chart
2026/11/20 13:29 UpdatedPrice Trend
2026/11/20 13:29 UpdatedPrice & Trading Details
2026/11/20 13:29 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/08/06 | ¥9.62 | ¥17.76 | +84.7% |
| 2026/05/11 | ¥9.20 | ¥22.45 | +143.9% |
| 2026/02/12 | ¥18.96 | ¥12.87 | -32.1% |
| 2025/11/06 | ¥16.21 | ¥18.03 | +11.2% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
Artisan Partners Funds Inc.-Artisan International Value Fund
|
49.4M | +20.49% | |
|
Dodge & Cox Funds-Dodge & Cox International Stock Fund
|
21.4M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
15.6M | +0.31% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
10.3M | +0.34% | |
|
Bridge Builder Trust-Bridge Builder International Equity Fund
|
8.8M | -0.23% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
8.0M | +1.30% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
40.8K | +1.06% |
Dividend History 4Years Growth
Updated 2026/11/22| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥30 | +50.0% |
| 2025 | ¥20 | +11.1% |
| 2024 | ¥18 | +12.5% |
| 2023 | ¥16 | +14.3% |
| 2022 | ¥14 | - |
Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥750,123M | ¥881,923M | ¥925,752M | ¥997,332M |
| Gross Profit | ¥506,700M | ¥596,849M | ¥618,432M | ¥683,697M |
| Operating Income | ¥144,696M | ¥186,118M | ¥51,745M | ¥161,996M |
| Pretax Income | ¥147,539M | ¥190,469M | ¥53,907M | ¥165,911M |
| Net Income | ¥115,742M | ¥143,432M | ¥242,566M | ¥117,855M |
| EPS | ¥90.17 | ¥113.08 | ¥199.44 | ¥102.80 |
| Operating Margin | 19.29% | 21.10% | 5.59% | 16.24% |
| Balance Sheet | ||||
| Total Assets | ¥1,357,999M | ¥1,508,701M | ¥1,534,216M | ¥1,432,826M |
| Total Equity | ¥510,168M | ¥640,085M | ¥757,186M | ¥751,733M |
| Total Liabilities | ¥847,831M | ¥868,616M | ¥777,030M | ¥681,093M |
| Cash | ¥302,572M | ¥169,329M | ¥340,933M | ¥252,532M |
| Interest-bearing Debt | ¥386,127M | ¥340,057M | ¥299,616M | ¥229,102M |
| Equity Ratio | 37.57% | 42.43% | 49.35% | 52.47% |
| D/E Ratio | 0.76 | 0.53 | 0.40 | 0.30 |
| Cash Flow | ||||
| Operating CF | ¥169,729M | ¥98,490M | ¥42,365M | ¥190,463M |
| Investing CF | -¥71,016M | -¥58,414M | ¥359,992M | -¥65,469M |
| Financing CF | -¥40,667M | -¥143,178M | -¥276,010M | -¥211,542M |
| Free CF | ¥107,958M | ¥27,867M | -¥22,259M | ¥125,254M |
| Efficiency | ||||
| ROE | 22.69% | 22.41% | 32.04% | 15.68% |
| ROA | 8.52% | 9.51% | 15.81% | 8.23% |
Latest IR Information
-
Fiscal Year Ending March 2027 Q2 Consolidated Financial Summary
Revenue was 269.2 billion yen (Year-over-Year +9%), adjusted operating margin 17.8%, adjusted EPS 32 yen. The first half demonstrates progress against the FY2027–FY2029 plan, with continued growth in GIS and urology/respiratory segments. Full-year outlook has been revised upward. Impact from...
Read more -
FY2027 Q2 Earnings Reference Materials
Full-year sales for FY2027 are expected to be 1,055,000 hundred million yen to 1,076,000 hundred million yen. Operating income is guided at 136,500 hundred million yen to 155,500 hundred million yen, and EBITDA at 204,500 hundred million yen to 223,500...
Read more -
Fiscal Year Ending March 2027 Second Quarter Financial Summary [IFRS] (Consolidated)
Consolidated interim results for the fiscal year ending March 2027 showed revenue of 509,593 million yen (12.2% YoY increase), adjusted operating income of 95,833 million yen (89.6% YoY increase), and net income attributable to owners of parent of 52,146 million...
Read more -
Notice Regarding Issuance of Import Alerts by the FDA
The FDA-issued import alert restricts importation into the United States of certain products from the affected facilities. No additional impact on consolidated results for the fiscal year ending March 2027 is expected. Existing products maintain safety and effectiveness when used...
Read more -
Notice Regarding Receipt of Warning Letter from the FDA
Received a Warning Letter from the FDA. A total of 6 sites are subject. Corrective and preventive actions have been implemented, and a response will be submitted to the FDA within 15 business days. There are no restrictions on product...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,085
Rating Score: 2.64 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
It Should Have Been Zuiko - PetaPixel ↗
Company Information
About
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.